236 related articles for article (PubMed ID: 25092414)
1. Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics.
Murray JM; Thompson AM; Vitsky A; Hawes M; Chuang WL; Pacheco J; Wilson S; McPherson JM; Thurberg BL; Karey KP; Andrews L
Mol Genet Metab; 2015 Feb; 114(2):217-25. PubMed ID: 25092414
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann-Pick disease.
Ziegler RJ; Brown C; Barbon CM; D'Angona AM; Schuchman EH; Andrews L; Thurberg BL; McPherson JM; Karey KP; Cheng SH
Mol Genet Metab; 2009 May; 97(1):35-42. PubMed ID: 19231265
[TBL] [Abstract][Full Text] [Related]
3. Liposome-targeted recombinant human acid sphingomyelinase: Production, formulation, and in vitro evaluation.
Aldosari MH; de Vries RP; Rodriguez LR; Hesen NA; Beztsinna N; van Kuilenburg ABP; Hollak CEM; Schellekens H; Mastrobattista E
Eur J Pharm Biopharm; 2019 Apr; 137():185-195. PubMed ID: 30818011
[TBL] [Abstract][Full Text] [Related]
4. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.
Wasserstein MP; Jones SA; Soran H; Diaz GA; Lippa N; Thurberg BL; Culm-Merdek K; Shamiyeh E; Inguilizian H; Cox GF; Puga AC
Mol Genet Metab; 2015; 116(1-2):88-97. PubMed ID: 26049896
[TBL] [Abstract][Full Text] [Related]
5. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease.
Dodge JC; Clarke J; Treleaven CM; Taksir TV; Griffiths DA; Yang W; Fidler JA; Passini MA; Karey KP; Schuchman EH; Cheng SH; Shihabuddin LS
Exp Neurol; 2009 Feb; 215(2):349-57. PubMed ID: 19059399
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of recombinant acid sphingomyelinase administration by different routes in niemann-pick disease mice.
Bae JS; Jang KH; Schuchman TR; Jin HK
Exp Anim; 2004 Oct; 53(5):417-21. PubMed ID: 15516789
[TBL] [Abstract][Full Text] [Related]
7. Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse.
Yang WW; Dodge JC; Passini MA; Taksir TV; Griffiths D; Schuchman EH; Cheng SH; Shihabuddin LS
Exp Neurol; 2007 Oct; 207(2):258-66. PubMed ID: 17686472
[TBL] [Abstract][Full Text] [Related]
8. Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology.
Miranda SR; He X; Simonaro CM; Gatt S; Dagan A; Desnick RJ; Schuchman EH
FASEB J; 2000 Oct; 14(13):1988-95. PubMed ID: 11023983
[TBL] [Abstract][Full Text] [Related]
9. Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency).
McGovern MM; Wasserstein MP; Kirmse B; Duvall WL; Schiano T; Thurberg BL; Richards S; Cox GF
Genet Med; 2016 Jan; 18(1):34-40. PubMed ID: 25834946
[TBL] [Abstract][Full Text] [Related]
10. AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease.
Barbon CM; Ziegler RJ; Li C; Armentano D; Cherry M; Desnick RJ; Schuchman EH; Cheng SH
Mol Ther; 2005 Sep; 12(3):431-40. PubMed ID: 16099409
[TBL] [Abstract][Full Text] [Related]
11. Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy.
Dhami R; Schuchman EH
J Biol Chem; 2004 Jan; 279(2):1526-32. PubMed ID: 14557264
[TBL] [Abstract][Full Text] [Related]
12. Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A.
Buccinnà B; Piccinini M; Prinetti A; Scandroglio F; Prioni S; Valsecchi M; Votta B; Grifoni S; Lupino E; Ramondetti C; Schuchman EH; Giordana MT; Sonnino S; Rinaudo MT
J Neurochem; 2009 Apr; 109(1):105-15. PubMed ID: 19187445
[TBL] [Abstract][Full Text] [Related]
13. Sphingomyelin 16:0 is a therapeutic target for neuronal death in acid sphingomyelinase deficiency.
Gaudioso Á; Jiang X; Casas J; Schuchman EH; Ledesma MD
Cell Death Dis; 2023 Apr; 14(4):248. PubMed ID: 37024473
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel biomarkers for Niemann-Pick disease using gene expression analysis of acid sphingomyelinase knockout mice.
Dhami R; Passini MA; Schuchman EH
Mol Ther; 2006 Mar; 13(3):556-64. PubMed ID: 16214420
[TBL] [Abstract][Full Text] [Related]
15. Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency.
Thurberg BL; Wasserstein MP; Jones SA; Schiano TD; Cox GF; Puga AC
Am J Surg Pathol; 2016 Sep; 40(9):1232-42. PubMed ID: 27340749
[TBL] [Abstract][Full Text] [Related]
16. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease.
Pérez-Cañamás A; Benvegnù S; Rueda CB; Rábano A; Satrústegui J; Ledesma MD
Mol Psychiatry; 2017 May; 22(5):711-723. PubMed ID: 27620840
[TBL] [Abstract][Full Text] [Related]
17. An enzymatic assay for quantifying sphingomyelin in tissues and plasma from humans and mice with Niemann-Pick disease.
He X; Chen F; Gatt S; Schuchman EH
Anal Biochem; 2001 Jun; 293(2):204-11. PubMed ID: 11399033
[TBL] [Abstract][Full Text] [Related]
18. [Study of acid sphingomyelinase in Niemann-Pick mice].
Sakiyama T; Kitagawa T
Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):484-90. PubMed ID: 2024027
[No Abstract] [Full Text] [Related]
19. Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells.
He X; Miranda SR; Xiong X; Dagan A; Gatt S; Schuchman EH
Biochim Biophys Acta; 1999 Jul; 1432(2):251-64. PubMed ID: 10407147
[TBL] [Abstract][Full Text] [Related]
20. Improvement of biochemical and behavioral defects in the Niemann-Pick type A mouse by intraventricular infusion of MARCKS.
Trovò L; Stroobants S; D'Hooge R; Ledesma MD; Dotti CG
Neurobiol Dis; 2015 Jan; 73():319-26. PubMed ID: 25251606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
